Monitoring relapsing remitting MS patients

Dennis Bourdette, Jack Antel, Henry McFarland, Erwin Montgomery

Research output: Contribution to journalArticle

Abstract

The availability of safe and partially effective disease modifying therapies necessitates changes in how neurologists monitor patients with relapsing remitting multiple sclerosis (RRMS). Neurologists need to make the diagnosis of MS as soon as possible to be able to initiate therapy early in the course of disease. In deciding whom to treat, neurologists should consider information on disease activity and burden acquired from the neurologic history and examination and magnetic resonance imaging (MRI). Patients not on a disease modifying therapy should undergo yearly clinical assessments and periodic cerebral MRI to monitor for changes in disease activity. Patients on disease modifying therapy should undergo regular clinical assessments to monitor for side-effects and disease activity. Cerebral MRI scanning may also be useful in assessing patients on therapy, particularly when considering changes in therapy. Copyright (C) 1999 Elsevier Science B.V.

Original languageEnglish (US)
Pages (from-to)16-21
Number of pages6
JournalJournal of Neuroimmunology
Volume98
Issue number1
DOIs
StatePublished - Jul 1 1999
Externally publishedYes

Fingerprint

Magnetic Resonance Imaging
Therapeutics
Relapsing-Remitting Multiple Sclerosis
Neurologic Examination
History
Neurologists

Keywords

  • Immunomodulation
  • Magnetic resonance imaging
  • Multiple sclerosis
  • Treatment

ASJC Scopus subject areas

  • Immunology
  • Clinical Neurology
  • Immunology and Allergy
  • Neurology

Cite this

Bourdette, D., Antel, J., McFarland, H., & Montgomery, E. (1999). Monitoring relapsing remitting MS patients. Journal of Neuroimmunology, 98(1), 16-21. https://doi.org/10.1016/S0165-5728(99)00076-4

Monitoring relapsing remitting MS patients. / Bourdette, Dennis; Antel, Jack; McFarland, Henry; Montgomery, Erwin.

In: Journal of Neuroimmunology, Vol. 98, No. 1, 01.07.1999, p. 16-21.

Research output: Contribution to journalArticle

Bourdette, D, Antel, J, McFarland, H & Montgomery, E 1999, 'Monitoring relapsing remitting MS patients', Journal of Neuroimmunology, vol. 98, no. 1, pp. 16-21. https://doi.org/10.1016/S0165-5728(99)00076-4
Bourdette D, Antel J, McFarland H, Montgomery E. Monitoring relapsing remitting MS patients. Journal of Neuroimmunology. 1999 Jul 1;98(1):16-21. https://doi.org/10.1016/S0165-5728(99)00076-4
Bourdette, Dennis ; Antel, Jack ; McFarland, Henry ; Montgomery, Erwin. / Monitoring relapsing remitting MS patients. In: Journal of Neuroimmunology. 1999 ; Vol. 98, No. 1. pp. 16-21.
@article{cb3b4b61c1db4acb9d000fc525d47236,
title = "Monitoring relapsing remitting MS patients",
abstract = "The availability of safe and partially effective disease modifying therapies necessitates changes in how neurologists monitor patients with relapsing remitting multiple sclerosis (RRMS). Neurologists need to make the diagnosis of MS as soon as possible to be able to initiate therapy early in the course of disease. In deciding whom to treat, neurologists should consider information on disease activity and burden acquired from the neurologic history and examination and magnetic resonance imaging (MRI). Patients not on a disease modifying therapy should undergo yearly clinical assessments and periodic cerebral MRI to monitor for changes in disease activity. Patients on disease modifying therapy should undergo regular clinical assessments to monitor for side-effects and disease activity. Cerebral MRI scanning may also be useful in assessing patients on therapy, particularly when considering changes in therapy. Copyright (C) 1999 Elsevier Science B.V.",
keywords = "Immunomodulation, Magnetic resonance imaging, Multiple sclerosis, Treatment",
author = "Dennis Bourdette and Jack Antel and Henry McFarland and Erwin Montgomery",
year = "1999",
month = "7",
day = "1",
doi = "10.1016/S0165-5728(99)00076-4",
language = "English (US)",
volume = "98",
pages = "16--21",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Monitoring relapsing remitting MS patients

AU - Bourdette, Dennis

AU - Antel, Jack

AU - McFarland, Henry

AU - Montgomery, Erwin

PY - 1999/7/1

Y1 - 1999/7/1

N2 - The availability of safe and partially effective disease modifying therapies necessitates changes in how neurologists monitor patients with relapsing remitting multiple sclerosis (RRMS). Neurologists need to make the diagnosis of MS as soon as possible to be able to initiate therapy early in the course of disease. In deciding whom to treat, neurologists should consider information on disease activity and burden acquired from the neurologic history and examination and magnetic resonance imaging (MRI). Patients not on a disease modifying therapy should undergo yearly clinical assessments and periodic cerebral MRI to monitor for changes in disease activity. Patients on disease modifying therapy should undergo regular clinical assessments to monitor for side-effects and disease activity. Cerebral MRI scanning may also be useful in assessing patients on therapy, particularly when considering changes in therapy. Copyright (C) 1999 Elsevier Science B.V.

AB - The availability of safe and partially effective disease modifying therapies necessitates changes in how neurologists monitor patients with relapsing remitting multiple sclerosis (RRMS). Neurologists need to make the diagnosis of MS as soon as possible to be able to initiate therapy early in the course of disease. In deciding whom to treat, neurologists should consider information on disease activity and burden acquired from the neurologic history and examination and magnetic resonance imaging (MRI). Patients not on a disease modifying therapy should undergo yearly clinical assessments and periodic cerebral MRI to monitor for changes in disease activity. Patients on disease modifying therapy should undergo regular clinical assessments to monitor for side-effects and disease activity. Cerebral MRI scanning may also be useful in assessing patients on therapy, particularly when considering changes in therapy. Copyright (C) 1999 Elsevier Science B.V.

KW - Immunomodulation

KW - Magnetic resonance imaging

KW - Multiple sclerosis

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0033047928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033047928&partnerID=8YFLogxK

U2 - 10.1016/S0165-5728(99)00076-4

DO - 10.1016/S0165-5728(99)00076-4

M3 - Article

VL - 98

SP - 16

EP - 21

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

IS - 1

ER -